Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Metastatic castration-resistant prostate cancer and PARP inhibitors: From tumor genomics to new therapeutic combinations].
Oudard S, Timsit MO, Maillet D, Mouillet G, Campedel L, Colomba É, Dourthe LM, Eymard JC, Gobert A, Jamet C, Joly C, Serrate C, Ploussard G. Oudard S, et al. Among authors: serrate c. Bull Cancer. 2025 Jan;112(1):61-81. doi: 10.1016/j.bulcan.2024.05.008. Epub 2024 Sep 3. Bull Cancer. 2025. PMID: 39232886 Free article. Review. French.
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
Pfister C, Gravis G, Flechon A, Chevreau C, Mahammedi H, Laguerre B, Guillot A, Joly F, Soulie M, Allory Y, Harter V, Culine S; VESPER Trial Investigators. Pfister C, et al. Lancet Oncol. 2024 Feb;25(2):255-264. doi: 10.1016/S1470-2045(23)00587-9. Epub 2023 Dec 21. Lancet Oncol. 2024. PMID: 38142702 Clinical Trial.
Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial.
Culine S, Harter V, Gravis G, Fléchon A, Chevreau C, Mahammedi H, Laguerre B, Guillot A, Joly F, Abadie-Lacourtoisie S, Geoffrois L, Fiore FD, Roubaud G, Barthélémy P, Voog E, Emambux S, Serrate C, Saldana C, Nguyen-Tan-Hon T, Loriot Y, Eymard JC, Huillard O, Rolland F, Houédé N, Spano JP, Demery ME, Vieillot S, L'Haridon T, Hilgers W, Allory Y, Pfister C; VESPER Trial Investigators. Culine S, et al. Among authors: serrate c. Clin Genitourin Cancer. 2021 Dec;19(6):554-562. doi: 10.1016/j.clgc.2021.08.005. Epub 2021 Sep 8. Clin Genitourin Cancer. 2021. PMID: 34602349 Clinical Trial.
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study.
Culine S, Fléchon A, Gravis G, Roubaud G, Loriot Y, Joly F, Barthélémy P, Assaf E, Mahammedi H, Beuzeboc P, Houédé N, Rolland F, Guillot A, Gross-Goupil M, Spano JP, Tartas S, Deblock M, Chevreau C, Serrate C, Manduzio H, Habibian M, Thézénas S, Allory Y. Culine S, et al. Among authors: serrate c. Clin Genitourin Cancer. 2021 Aug;19(4):e216-e222. doi: 10.1016/j.clgc.2021.02.005. Epub 2021 Feb 24. Clin Genitourin Cancer. 2021. PMID: 33753043 Clinical Trial.
[Management of metastatic bladder cancer].
Gauthier H, Serrate C, Pouessel D, Le Maignan C, Teixeira L, Culine S. Gauthier H, et al. Among authors: serrate c. Rev Prat. 2014 Dec;64(10):1405-7. Rev Prat. 2014. PMID: 25668832 French.
16 results